|21.54||-0.8500||-3.80%||Vol 957.36K||1Y Perf -56.61%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||0.01 0.05%|
|Target Price||77.67||Analyst Rating||Moderate Buy 1.57|
|Potential %||260.59||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 43.94|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||1.56||Earnings Rating||—|
|Market Cap||1.71B||Earnings Date||6th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th Nov 2023|
|Estimated EPS Next Report||-1.32|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||916.96K|
|Avg. Monthly Volume||926.18K|
|Avg. Quarterly Volume||846.02K|
Beam Therapeutics Inc. (NASDAQ: BEAM) stock closed at 22.39 per share at the end of the most recent trading day (a 4.14% change compared to the prior day closing price) with a volume of 975.14K shares and market capitalization of 1.71B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 166 people. Beam Therapeutics Inc. CEO is John Evans.
The one-year performance of Beam Therapeutics Inc. stock is -56.61%, while year-to-date (YTD) performance is -42.75%. BEAM stock has a five-year performance of %. Its 52-week range is between 21.02 and 54.3, which gives BEAM stock a 52-week price range ratio of 1.56%
Beam Therapeutics Inc. currently has a PE ratio of -9.00, a price-to-book (PB) ratio of 3.98, a price-to-sale (PS) ratio of 66.67, a price to cashflow ratio of 29.90, a PEG ratio of -, a ROA of -25.17%, a ROC of -33.51% and a ROE of -40.23%. The company’s profit margin is -%, its EBITDA margin is -326.40%, and its revenue ttm is $40.88 Million , which makes it $0.58 revenue per share.
Of the last four earnings reports from Beam Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.32 for the next earnings report. Beam Therapeutics Inc.’s next earnings report date is 06th Nov 2023.
The consensus rating of Wall Street analysts for Beam Therapeutics Inc. is Moderate Buy (1.57), with a target price of $77.67, which is +260.59% compared to the current price. The earnings rating for Beam Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Beam Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Beam Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.12, ATR14 : 1.20, CCI20 : -197.38, Chaikin Money Flow : -0.02, MACD : -0.66, Money Flow Index : 24.71, ROC : -10.62, RSI : 38.68, STOCH (14,3) : 27.96, STOCH RSI : 0.47, UO : 46.14, Williams %R : -72.04), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Beam Therapeutics Inc. in the last 12-months were: Amy Simon (Sold 16 099 shares of value $480 843 ), Burrell Terry-Ann (Sold 0 shares of value $-1 332 104 ), Burrell Terry-Ann (Sold 109 325 shares of value $4 858 728 ), Christine Bellon (Sold 2 092 shares of value $61 996 ), Ciaramella Giuseppe (Option Excercise at a value of $54 371), Ciaramella Giuseppe (Sold 57 401 shares of value $2 121 648 ), Evans John (Sold 0 shares of value $-99 997 ), Evans John (Sold 11 654 shares of value $345 311 ), Giuseppe Ciaramella (Option Excercise at a value of $103 084), Giuseppe Ciaramella (Sold 108 416 shares of value $4 299 882 ), John Evans (Sold 11 654 shares of value $345 334 ), Simon Amy (Sold 391 shares of value $11 918 ), Terry-Ann Burrell (Option Excercise at a value of $1 332 104), Terry-Ann Burrell (Sold 109 325 shares of value $4 858 817 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.